U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H30Cl2N10.2C2H4O2
Molecular Weight 625.551
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORHEXIDINE ACETATE

SMILES

CC(O)=O.CC(O)=O.ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1

InChI

InChIKey=WDRFFJWBUDTUCA-UHFFFAOYSA-N
InChI=1S/C22H30Cl2N10.2C2H4O2/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18;2*1-2(3)4/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34);2*1H3,(H,3,4)

HIDE SMILES / InChI
Molecular Formula C2H4O2
Molecular Weight 60.052
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C22H30Cl2N10
Molecular Weight 505.447
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf http://www.drugbank.ca/drugs/DB00878 http://www.wikidoc.org/index.php/Chlorhexidine_gluconate

Chlorhexidine is a broad-spectrum biocide effective against Gram-positive bacteria, Gram-negative bacteria and fungi. It is used primarily as its salts (e.g., the dihydrochloride, diacetate, and digluconate). Chlorhexidine inactivates microorganisms with a broader spectrum than other antimicrobials (e.g. antibiotics) and has a quicker kill rate than other antimicrobials (e.g. povidone-iodine). It has both bacteriostatic (inhibits bacterial growth) and bactericidal (kills bacteria) mechanisms of action, depending on its concentration. Chlorhexidine kills by disrupting the cell membrane. The most common side effects associated with chlorhexidine gluconate oral rinses are: 1) an increase in staining of teeth and other oral surfaces; 2) an increase in calculus formation; and 3) an alteration in taste perception; 4) toothache; 5) upper respiratory tract infection; and 6) headache.

Originator

Imperial Chemical Industries
59
Curator's Comment: 1950s — Chlorhexidine is discovered by the Imperial Chemical Industries, Limited (Manchester, UK) while researching the synthesis of anti-malarial agents

Approval Year

1959
138
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
HIBICLENS

Approved Use

Use for the preparation of the patient's skin prior to surgery. Helps to reduce bacteria that potentially can cause skin infection.

Launch Date

1976
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2007 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9869352
2.5 mg single, dental
dose: 2.5 mg
route of administration: Dental
experiment type: SINGLE
co-administered:
CHLORHEXIDINE inflammatory exudate
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.206 μg/g
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORHEXIDINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
187083.4 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9869352
2.5 mg single, dental
dose: 2.5 mg
route of administration: Dental
experiment type: SINGLE
co-administered:
CHLORHEXIDINE inflammatory exudate
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
148287.6 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26271869
0.2 % single, dental
dose: 0.2 %
route of administration: Dental
experiment type: SINGLE
co-administered:
CHLORHEXIDINE saliva
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
180892.9 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/26271869
0.2 % 1 times / day multiple, dental
dose: 0.2 %
route of administration: Dental
experiment type: MULTIPLE
co-administered:
CHLORHEXIDINE saliva
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
17%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/4269593
CHLORHEXIDINE serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
73%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/4269593/
CHLORHEXIDINE saliva
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 % 1 times / day single, topical
Recommended
Dose: 2 %, 1 times / day
Route: topical
Route: single
Dose: 2 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 18-64 years
n = 36
Health Status: healthy
Age Group: 18-64 years
Sex: M+F
Population Size: 36
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
Other AEs: Redness...
Other AEs:
Redness (grade 2)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 18-79 years
n = 204
Health Status: healthy
Age Group: 18-79 years
Sex: M+F
Population Size: 204
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
Disc. AE: Papule, Erythema...
AEs leading to
discontinuation/dose reduction:
Papule
Erythema (grade 2)
Edema (grade 1)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 22-60 years
n = 23
Health Status: healthy
Age Group: 22-60 years
Sex: M+F
Population Size: 23
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
Disc. AE: Burning sensation, Petechial rash...
AEs leading to
discontinuation/dose reduction:
Burning sensation (grade 1)
Petechial rash (grade 1)
Scab
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
1.5 oz 1 times / day single, oral (mean)
Studied dose
Dose: 1.5 oz, 1 times / day
Route: oral
Route: single
Dose: 1.5 oz, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf
healthy, child
n = 1
Health Status: healthy
Age Group: child
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf
Other AEs: Distress epigastric, Nausea...
Other AEs:
Distress epigastric
Nausea
Alcohol intoxication
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Other AEs: Toothache, Upper respiratory tract infection...
Other AEs:
Toothache (50.7%)
Upper respiratory tract infection (28.4%)
Headache (27.1%)
Sinusitis (13.8%)
Influenza-like symptoms (7.6%)
Back pain (6.7%)
Tooth disorder (6.2%)
Bronchitis (6.2%)
Abscess (5.8%)
Pain (4.9%)
Allergy (4%)
Myalgia (4%)
Gum hyperplasia (3.6%)
Pharyngitis (3.6%)
Arthralgia (3.1%)
Dysmenorrhea (3.1%)
Dyspepsia (3.1%)
Rhinitis (2.7%)
Coughing (2.7%)
Arthrosis (2.7%)
Hypertension (2.2%)
Stomatitis ulcerative (2.2%)
Tendinitis (2.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
AEs

AEs

AESignificanceDosePopulation
Redness grade 2
2 % 1 times / day single, topical
Recommended
Dose: 2 %, 1 times / day
Route: topical
Route: single
Dose: 2 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 18-64 years
n = 36
Health Status: healthy
Age Group: 18-64 years
Sex: M+F
Population Size: 36
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
Papule Disc. AE
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 18-79 years
n = 204
Health Status: healthy
Age Group: 18-79 years
Sex: M+F
Population Size: 204
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
Edema grade 1
Disc. AE
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 18-79 years
n = 204
Health Status: healthy
Age Group: 18-79 years
Sex: M+F
Population Size: 204
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
Erythema grade 2
Disc. AE
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 18-79 years
n = 204
Health Status: healthy
Age Group: 18-79 years
Sex: M+F
Population Size: 204
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
Scab Disc. AE
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 22-60 years
n = 23
Health Status: healthy
Age Group: 22-60 years
Sex: M+F
Population Size: 23
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
Burning sensation grade 1
Disc. AE
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 22-60 years
n = 23
Health Status: healthy
Age Group: 22-60 years
Sex: M+F
Population Size: 23
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
Petechial rash grade 1
Disc. AE
3 % 1 times / day multiple, topical (mean)
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
healthy, 22-60 years
n = 23
Health Status: healthy
Age Group: 22-60 years
Sex: M+F
Population Size: 23
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf
Page: nda/2005/21669s000_MedR.pdf - p.83
Alcohol intoxication
1.5 oz 1 times / day single, oral (mean)
Studied dose
Dose: 1.5 oz, 1 times / day
Route: oral
Route: single
Dose: 1.5 oz, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf
healthy, child
n = 1
Health Status: healthy
Age Group: child
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf
Distress epigastric
1.5 oz 1 times / day single, oral (mean)
Studied dose
Dose: 1.5 oz, 1 times / day
Route: oral
Route: single
Dose: 1.5 oz, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf
healthy, child
n = 1
Health Status: healthy
Age Group: child
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf
Nausea
1.5 oz 1 times / day single, oral (mean)
Studied dose
Dose: 1.5 oz, 1 times / day
Route: oral
Route: single
Dose: 1.5 oz, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf
healthy, child
n = 1
Health Status: healthy
Age Group: child
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf
Sinusitis 13.8%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Hypertension 2.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Stomatitis ulcerative 2.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Tendinitis 2.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Arthrosis 2.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Coughing 2.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Rhinitis 2.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Headache 27.1%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Upper respiratory tract infection 28.4%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Arthralgia 3.1%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Dysmenorrhea 3.1%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Dyspepsia 3.1%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Gum hyperplasia 3.6%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Pharyngitis 3.6%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Allergy 4%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Myalgia 4%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Pain 4.9%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Abscess 5.8%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Toothache 50.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Bronchitis 6.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Tooth disorder 6.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Back pain 6.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Influenza-like symptoms 7.6%
2.5 mg 3 times / month multiple, subgingival
Recommended
Dose: 2.5 mg, 3 times / month
Route: subgingival
Route: multiple
Dose: 2.5 mg, 3 times / month
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
unhealthy, mean age 47 years
n = 225
Health Status: unhealthy
Condition: periodontitis
Age Group: mean age 47 years
Sex: M+F
Population Size: 225
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf
https://pubmed.ncbi.nlm.nih.gov/9776027/
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:3614
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3614
ChemicalBook
CB2771984
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2771984
ChemicalBook
CB4732251
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4732251
MolPort
MolPort-002-541-741
https://www.molport.com/shop/molecule-link/MolPort-002-541-741
MolPort
MolPort-006-167-649
https://www.molport.com/shop/molecule-link/MolPort-006-167-649
ZINC
ZINC000014768621
http://zinc15.docking.org/substances/ZINC000014768621
eMolecules
491622
https://www.emolecules.com/cgi-bin/more?vid=491622
PubMed

PubMed

TitleDatePubMed
Nephrotoxic and hepatotoxic effects of triclosan and chlorhexidine in rats.
1977 Oct
Combined effects of Zn(2+)-chlorhexidine and Zn(2+)-cetylpyridinium chloride on caries incidence in partially desalivated rats.
1991 Aug
Effects of chlorhexidine diacetate on Candida albicans, C. glabrata and Saccharomyces cerevisiae.
1992 Apr
6-month use of 0.2% delmopinol hydrochloride in comparison with 0.2% chlorhexidine digluconate and placebo. (I). Effect on plaque formation and gingivitis.
1998 Sep
[Contact sensitization to pharmaceutic aids in dermatologic cosmetic and external use preparations].
2004 May
Chlorhexidine induces DNA damage in rat peripheral leukocytes and oral mucosal cells.
2004 Oct
Chemoenzymatic synthesis and antimicrobial and haemolytic activities of amphiphilic bis(phenylacetylarginine) derivatives.
2006 Oct
Cysticidal effect on acanthamoeba and toxicity on human keratocytes by polyhexamethylene biguanide and chlorhexidine.
2007 Jul
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Patents

JP1026511A
5
JP1043250A
5
JP1090165A
5
JP2000109428A
5
JP2000178189A
5
JP2000229823A
11
JP2000512276A
5
JP2001123711A
5
JP2001521945A
47
JP2002154941A
5
JP2002179513A
6
JP2002519307A
6
JP2002533379A
53
JP2002539895A
5
JP2002542847A
5
JP2003252738A
5
JP2003521472A
7
JP2003529548A
5
JP2003531247A
7
JP2004035416A
5
JP2004520088A
9
JP2005263792A
5
JP2005306819A
7
JP2005515294A
5
JP2005515838A
5
JP2005537097A
12
JP2006143618A
5
JP2006193684A
5
JP2006514009A
48
JP2007084471A
6
JP2007308430A
6
JP2007513157A
5
JP2007516285A
8
JP2007522835A
6
JP2007536261A
5
JP2008023337A
5
JP2008222638A
5
JP2008525575A
6
JP2008543793A
5
JP2008546812A
6
JP2009073788A
5
JP2009501065A
33
JP2009517152A
5
JP2009526755A
447
JP2009528360A
86
JP2010505829A
10
JP2010508915A
8
JP2010510819A
7
JP2010527335A
5
JP2011037779A
5
JP2011051941A
5

Sample Use Guides

In Vivo Use Guide
Recommended use is twice daily oral rinsing for 30 seconds, morning and evening after tooth brushing. Usual dosage is 15 ml (1 tablespoon) of undiluted Chlorhexidine gluconate oral rinse. Prophylaxis intervals - no longer than six months.
Route of Administration: Topical
In Vitro Use Guide
Curator's Comment: Chlorhexidine caused significant decreases in both total anaerobe and total aerobe/facultative anaerobe counts (P < 0.05), together with lesser decreases in gram-negative anaerobes.
Minimum bactericidal concentrations are different for different bacterial strains (3.9-83.3 mg/l).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:00:58 GMT 2023
Edited
by admin
on Fri Dec 15 15:00:58 GMT 2023
Record UNII
5908ZUF22Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLORHEXIDINE ACETATE
GREEN BOOK   MART.   USP   USP-RS  
Common Name English
CHLORHEXIDINE DIACETATE [WHO-IP]
Common Name English
1,1'-HEXAMETHYLENEBIS(5-(4-CHLOROPHENYL)BIGUANIDE) DIACETATE
Systematic Name English
NSC-526936
Code English
CHLORHEXIDINE ACETATE [USP-RS]
Common Name English
CHLORHEXIDINE DIACETATE [EP MONOGRAPH]
Common Name English
CHLORHEXIDINI DIACETAS [WHO-IP LATIN]
Common Name English
CHLORHEXIDINE DIACETATE [INCI]
Common Name English
CHLORHEXIDINE DIACETATE
EP   INCI   MI   WHO-DD   WHO-IP  
INCI  
Official Name English
CHLORHEXIDINE ACETATE [MART.]
Common Name English
CHLORHEXIDINE ACETATE [GREEN BOOK]
Common Name English
CHLORHEXIDINE DIACETATE [MI]
Common Name English
CHLORHEXIDINE ACETATE [USP MONOGRAPH]
Common Name English
Chlorhexidine diacetate [WHO-DD]
Common Name English
Classification Tree Code System Code
EPA PESTICIDE CODE 45502
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
Code System Code Type Description
RXCUI
2359
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
ALTERNATIVE
RXCUI
133054
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
PRIMARY
CHEBI
81711
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
PRIMARY
RS_ITEM_NUM
1111103
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
PRIMARY
PUBCHEM
5967
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
PRIMARY
EPA CompTox
DTXSID7032345
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
PRIMARY
NSC
526936
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
PRIMARY
MERCK INDEX
m3362
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
PRIMARY Merck Index
DAILYMED
5908ZUF22Y
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
PRIMARY
SMS_ID
100000092204
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
PRIMARY
DRUG BANK
DBSALT001123
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
PRIMARY
FDA UNII
5908ZUF22Y
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
PRIMARY
CAS
56-95-1
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-302-4
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
PRIMARY
EVMPD
SUB20822
Created by admin on Fri Dec 15 15:00:58 GMT 2023 , Edited by admin on Fri Dec 15 15:00:58 GMT 2023
PRIMARY
Related Record Type Details
Structure of CHLORHEXIDINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of 4-CHLOROPHENYLUREA
IMPURITY -> PARENT
Structure of N-(4-CHLOROPHENYL)GUANIDINE
IMPURITY -> PARENT
Structure of N<SUP>1</SUP>-(6-((N-(N-(4-CHLOROPHENYL)CARBAMIMIDOYL)CARBAMIMIDOYL)AMINO)HEXYL)-N<SUP>3</SUP>-PHENYLIMIDODICARBONIMIDIC DIAMIDE
IMPURITY -> PARENT
Structure of N-(N-(6-((N-(N-(4-CHLOROPHENYL)CARBAMIMIDOYL)CARBAMIMIDOYL)AMINO)HEXYL)CARBAMIMIDOYL)UREA
IMPURITY -> PARENT
Structure of OXOCHLORHEXIDINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-(6-Aminohexyl)-N′-(4-chlorophenyl)imidodicarbonimidic diamide
IMPURITY -> PARENT
Structure of CHLORHEXIDINE NITRILE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of CHLORHEXIDINE DIMER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N<SUP>1</SUP>-(2-Chlorophenyl)-N<SUP>14</SUP>-(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
IMPURITY -> PARENT
Structure of CHLORHEXIDINE GUANIDINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of CHLORHEXIDINE
ACTIVE MOIETY
Description. A white or yellowish white, microcrystalline powder; odourless or almost odourless. Solubility. Soluble in 55 parts of water and in 15 parts of ethanol (~750 g/l) TS; very slightly soluble in glycerol R. Category. Disinfectant. Storage. Chlorhexidine diacetate should be kept in a well-closed container, protected from light.
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966